We used 2 commercially available antibody tests to estimate seroprevalence of severe acute respiratory syndrome coronavirus 2 infection in Japan during June 2020. Of 7,950 samples, 8 were positive by both assays. Using 2 reliable antibody tests in conjunction is an effective method for estimating seroprevalence in low prevalence settings.
Keywords: 2019 novel coronavirus disease; COVID-19; Japan; SARS-CoV-2; antibodies; antibody responses; coronavirus; coronavirus disease; diagnostics; immunology; respiratory infections; serology; seroprevalence; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.